Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.
Nan An, Jiaying Chen, Jibin Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This study conducted a matching-adjusted indirect comparison of fruquintinib plus paclitaxel versus ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. The analysis, based on data from 703 and 440 patients respectively, found that fruquintinib significantly improved progression-free survival (PFS) with a hazard ratio of 0.70 (95% CI: 0.51-0.96; p = 0.0280), indicating a 30% reduction in progression risk.
Key findings
- Fruquintinib plus paclitaxel improved PFS compared to ramucirumab plus paclitaxel (HR: 0.70; p = 0.0280).
- Fruquintinib achieved a significantly higher overall response rate (OR: 1.76; p = 0.008).
- Fruquintinib also showed a higher disease control rate (OR: 1.94; p < 0.001).
- The incidence of increased bilirubin was higher with fruquintinib (RD: 12.3%; p < 0.05).
Why it matters
The findings provide important comparative evidence for clinicians regarding second-line treatment options for advanced gastric or gastroesophageal junction adenocarcinoma, particularly in the absence of direct head-to-head trials.